Suppr超能文献

LGR4,一种具有全身作用的 G 蛋白偶联受体:从发育到代谢调节。

LGR4, a G Protein-Coupled Receptor With a Systemic Role: From Development to Metabolic Regulation.

机构信息

Department of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.

出版信息

Front Endocrinol (Lausanne). 2022 May 30;13:867001. doi: 10.3389/fendo.2022.867001. eCollection 2022.

Abstract

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4/GPR48), a member of the GPCR (G protein-coupled receptors) superfamily, subfamily B, is a common intestinal crypt stem cell marker. It binds R-spondins/Norrin as classical ligands and plays a crucial role in Wnt signaling potentiation. Interaction between LGR4 and R-spondins initiates many Wnt-driven developmental processes, e.g., kidney, eye, or reproductive tract formation, as well as intestinal crypt (Paneth) stem cell pool maintenance. Besides the well-described role of LGR4 in development, several novel functions of this receptor have recently been discovered. In this context, LGR4 was indicated to participate in TGFβ and NFκB signaling regulation in hematopoietic precursors and intestinal cells, respectively, and found to be a new, alternative receptor for RANKL (Receptor Activator of NF kappa B Ligand) in bone cells. LGR4 inhibits the process of osteoclast differentiation, by antagonizing the interaction between RANK (Receptor Activator of NF kappa B) and its ligand-RANKL. It is also known to trigger anti-inflammatory responses in different tissues (liver, intestine, cardiac cells, and skin), serve as a sensor of the circadian clock in the liver, regulate adipogenesis and energy expenditure in adipose tissue and skeletal muscles, respectively. The extracellular domain of LGR4 (LGR4-ECD) has emerged as a potential new therapeutic for osteoporosis and cancer. LGR4 integrates different signaling pathways and regulates various cellular processes vital for maintaining whole-body homeostasis. Yet, the role of LGR4 in many cell types (e.g. pancreatic beta cells) and diseases (e.g., diabetes) remains to be elucidated. Considering the broad spectrum of LGR4 actions, this review aims to discuss both canonical and novel roles of LGR4, with emphasis on emerging research directions focused on this receptor.

摘要

富含亮氨酸重复序列的 G 蛋白偶联受体 4(LGR4/GPR48)是 GPCR(G 蛋白偶联受体)超家族 B 亚家族的成员,是一种常见的肠隐窝干细胞标志物。它作为经典配体与 R 脊椎蛋白/Norrin 结合,在 Wnt 信号增强中发挥关键作用。LGR4 与 R 脊椎蛋白的相互作用启动了许多 Wnt 驱动的发育过程,例如肾脏、眼睛或生殖道的形成,以及肠隐窝(潘氏)干细胞池的维持。除了 LGR4 在发育中的作用外,最近还发现了该受体的几个新功能。在这种情况下,LGR4 被表明分别参与造血前体细胞和肠细胞中的 TGFβ 和 NFκB 信号调节,并被发现是骨细胞中 RANKL(核因子 κ B 配体受体激活剂)的新替代受体。LGR4 通过拮抗 RANK(核因子 κ B 受体激活剂)与其配体-RANKL 之间的相互作用,抑制破骨细胞分化过程。它还已知在不同组织(肝脏、肠道、心脏细胞和皮肤)中引发抗炎反应,作为肝脏中生物钟的传感器,分别调节脂肪组织和骨骼肌中的脂肪生成和能量消耗。LGR4 的细胞外结构域(LGR4-ECD)已成为治疗骨质疏松症和癌症的潜在新疗法。LGR4 整合了不同的信号通路,调节了维持全身内稳态至关重要的各种细胞过程。然而,LGR4 在许多细胞类型(例如胰岛 β 细胞)和疾病(例如糖尿病)中的作用仍有待阐明。鉴于 LGR4 作用的广泛多样性,本综述旨在讨论 LGR4 的经典和新型作用,重点介绍集中在该受体上的新兴研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cee3/9190282/4b2218bc84a2/fendo-13-867001-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验